Comparison of Secukinumab Vs Infliximab in a Cost Per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthrisis at 48 Weeks from a Moroccan Perspective

OBJECTIVES: The objective of this analysis was to estimate and compare the long-term cost per responder (CPR) based on the American College of Rheumatology outcomes (ACR 20/50/70) following 48 weeks of psoriatic arthritis (PsA) treatment with secukinumab (SEC, anti-IL-17A ) and 54 weeks with infliximab (INF, anti-TNF). METHODS: The CPR for each treatment was estimated by dividing the drug acquisition cost by its response rate. Drug costs were estimated on the basis of the official Agence nationale de l'Assurance Maladie website (currency in MAD) and the number of doses required for one year (week 52 for SEC; week 54 for INF). The long-term response rates were derived from a previous matching-adjusted indirect comparison (MAIC) based on the data from FUTURE 2 (SEC) and IMPACT 2 (INF) clinical trials. MAIC analysis matched the populations on key baseline characteristics. RESULTS: MAIC analysis showed higher ACR (20/50/70) response rates for SEC 150mg and 300mg (week 52) compared to INF (week 54) for biologic-naive patients. ACR 20 response rates were 88%, 77% and 59% whereas ACR 50 response rates were 45%, 68% and 37%, and ACR 70 response rates were 22%, 31% and 22% for SEC 150mg, 300 mg and INF respectively. Among PsA patients, cost per ACR20 responder were MAD 101,042.00, MAD 228,740.00 and MAD 288,469.00, cost per ACR50 responder were MAD 197,670.00, MAD 262,048.00 and MAD 463,298.00, whereas costs per ACR70 responder were MAD 408,616.00, MAD 567,361.00 and MAD 764,442.00 for SEC 150mg, SEC 300mg and INF respectively. CONCLUSIONS: ACR (20/50/70) response rates were higher for SEC 150mg and 300mg compared to INF at one year (SEQweek 52; INF:week54).The cost per response for all ACR response rates at 48 weeks were consistently lower for SEC vs. INF. PsA patients could be treated more efficient and effectively with SEC versus INF in Morocco.